BioAge Labs, Inc. (BIOA)
8.06
-0.03
(-0.37%)
USD |
NASDAQ |
Sep 18, 16:00
8.06
0.00 (0.00%)
After-Hours: 20:00
BioAge Labs Cash from Investing (Quarterly) : -164.51M for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -164.51M |
| March 31, 2026 | -46.75M |
| December 31, 2025 | -14.43M |
| September 30, 2025 | 12.84M |
| June 30, 2025 | -15.64M |
| March 31, 2025 | -77.99M |
| December 31, 2024 | -0.026M |
| Date | Value |
|---|---|
| September 30, 2024 | -0.305M |
| June 30, 2024 | -0.035M |
| March 31, 2024 | 0.00 |
| December 31, 2023 | 0.00 |
| September 30, 2023 | -0.099M |
| June 30, 2023 | -0.056M |
| March 31, 2023 | -0.111M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Eli Lilly & Co. | -15.40B |
| Pfizer Inc. | 2.106B |
| Oramed Pharmaceuticals, Inc. | 3.920M |
| Liquidia Corp. | -12.24M |
| Neumora Therapeutics, Inc. | 0.00 |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -19.26M |
| Cash from Financing (Quarterly) | 15.97M |
| Free Cash Flow | -88.09M |
| Free Cash Flow Per Share (Quarterly) | -0.4369 |
| Free Cash Flow to Equity (Quarterly) | -18.39M |
| Free Cash Flow to Firm (Quarterly) | -19.59M |
| Free Cash Flow Yield | -27.45% |